NASDAQ:IPSC

Century Therapeutics - IPSC Stock Forecast, Price & News

$10.56

+0.06 (+0.57%)

(As of 12/1/2022 12:00 AM ET)

Add

Compare

Today's Range: $10.22
▼
$10.63
50-Day Range: $9.32
▼
$11.58
52-Week Range: $7.32
▼
$19.39

Volume: 46,213 shs
Average Volume: 92,090 shs
Market Capitalization: $622.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.33

Century Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 139.9% Upside
$25.33 Price Target
Short Interest: Bearish
9.26% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.90
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.33) to ($2.52) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

752nd out of 1,047 stocks

Biological Products, Except Diagnostic Industry

123rd out of 173 stocks

4.4

Analyst's Opinion

Consensus Rating
Century Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.33, Century Therapeutics has a forecasted upside of 139.9% from its current price of $10.56.
Amount of Analyst Coverage
Century Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
9.26% of the float of Century Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Century Therapeutics has a short interest ratio ("days to cover") of 24, which indicates bearish sentiment.
Change versus previous month
Short interest in Century Therapeutics has recently increased by 2.29%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Century Therapeutics does not currently pay a dividend.
Dividend Growth
Century Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IPSC.

3.3

News and Social Media Coverage

News Sentiment
Century Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Century Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Century Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.30% of the stock of Century Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 36.97% of the stock of Century Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Century Therapeutics are expected to decrease in the coming year, from ($2.33) to ($2.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Century Therapeutics is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Century Therapeutics is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Century Therapeutics has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Century Therapeutics (NASDAQ:IPSC) Stock

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IPSC Stock News Headlines

December 2, 2022 | americanbankingnews.com

Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $25.33 Consensus Price Target from Brokerages

November 29, 2022 | americanbankingnews.com

Century Therapeutics, Inc. (NASDAQ:IPSC) to Post FY2022 Earnings of ($2.37) Per Share, SVB Leerink Forecasts

November 27, 2022 | americanbankingnews.com

Century Therapeutics (NASDAQ:IPSC) & ADMA Biologics (NASDAQ:ADMA) Head to Head Survey

November 22, 2022 | finance.yahoo.com

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

November 11, 2022 | finance.yahoo.com

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

November 10, 2022 | finanznachrichten.de

Century Therapeutics, Inc.: Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 10, 2022 | finance.yahoo.com

Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 10, 2022 | finance.yahoo.com

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

November 2, 2022 | finance.yahoo.com

Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022

October 5, 2022 | finance.yahoo.com

Century Therapeutics to Present at the SITC 37th Annual Meeting

October 3, 2022 | finance.yahoo.com

Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors

September 26, 2022 | benzinga.com

Century Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference

September 26, 2022 | finance.yahoo.com

Century Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 6, 2022 | finance.yahoo.com

Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 27, 2022 | seekingalpha.com

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

August 25, 2022 | markets.businessinsider.com

FDA Announced Clearance To Century Therapeutics' Allogeneic Cell Therapy Candidate Study

August 25, 2022 | finance.yahoo.com

Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection

August 15, 2022 | nasdaq.com

Investors in Century Therapeutics (NASDAQ:IPSC) have unfortunately lost 62% over the last year

August 11, 2022 | finance.yahoo.com

Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

August 11, 2022 | finance.yahoo.com

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates

July 1, 2022 | finance.yahoo.com

Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 13% this week, taking one-year losses to 71%

June 24, 2022 | seekingalpha.com

Century Therapeutics joins Russell Microcap® Index

June 24, 2022 | finance.yahoo.com

Century Therapeutics Announces Its Addition to the Russell Microcap® Index

June 21, 2022 | finance.yahoo.com

Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

June 6, 2022 | finance.yahoo.com

Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IPSC Company Calendar

Last Earnings: 11/10/2021
Today: 12/02/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/16/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IPSC
CUSIP: N/A
CIK: 1850119
Web: www.centurytx.com
Phone: 267-817-5790
Fax: N/A
Employees: 170
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $25.33
High Stock Price Forecast: $32.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +139.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-95,820,000.00
Net Margins: N/A
Pretax Margin: -2,722.15%
Return on Equity: -34.65%
Return on Assets: -25.09%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 13.44
Quick Ratio: 13.44

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.60 per share
Price / Book: 1.89

Miscellaneous

Outstanding Shares: 58,970,000
Free Float: 52,900,000
Market Cap: $622.72 million
Optionable: Not Optionable
Beta: 0.41

Key Executives

Dr. Osvaldo Flores Ph.D. (Age 59)
Pres, CEO & Director
Comp: $778.06k

Dr. Adrienne Farid Ph.D. (Age 60)
Chief Operations Officer
Comp: $589.47k

Dr. Luis Borges (Age 60)
Chief Scientific Officer
Comp: $604.12k

Mr. Douglas Carr CPA
VP of Fin. and Operations & Sec.

Dr. Gregory Russotti Ph.D. (Age 55)
Chief Technology Officer

Mr. Kenneth J. Dow J.D.
Head of Legal & Compliance

Dr. Shane Williams Ph.D.
Chief People Officer

Dr. Michael C. Diem (Age 51)
Chief Bus. Officer

Dr. Hyam I. Levitsky M.D. (Age 64)
Pres of R&D

Mr. Mark Wallet
Head of Immunology & VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IPSC Stock - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IPSC shares.
View IPSC analyst ratings or view top-rated stocks.
What is Century Therapeutics' stock price forecast for 2023?: 8 brokerages have issued twelve-month target prices for Century Therapeutics' shares. Their IPSC share price forecasts range from $15.00 to $32.00. On average, they expect the company's stock price to reach $25.33 in the next year. This suggests a possible upside of 139.9% from the stock's current price.
View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts.
How have IPSC shares performed in 2022?: Century Therapeutics' stock was trading at $15.86 at the beginning of 2022. Since then, IPSC stock has decreased by 33.4% and is now trading at $10.56.
View the best growth stocks for 2022 here.
When is Century Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our IPSC earnings forecast.
How were Century Therapeutics' earnings last quarter?: Century Therapeutics, Inc. (NASDAQ:IPSC) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.08.
When did Century Therapeutics IPO?: (IPSC) raised $201 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Century Therapeutics' stock symbol?: Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC."
Who are Century Therapeutics' major shareholders?: Century Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.39%), Vanguard Group Inc. (1.81%), Logos Global Management LP (0.78%), State Street Corp (0.55%), Point72 Asset Management L.P. (0.28%) and Bank of New York Mellon Corp (0.10%). Insiders that own company stock include Eli Casdin and Versant Venture Capital Vi, L.
View institutional ownership trends.
How do I buy shares of Century Therapeutics?: Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Century Therapeutics' stock price today?: One share of IPSC stock can currently be purchased for approximately $10.56.
How much money does Century Therapeutics make?: Century Therapeutics (NASDAQ:IPSC) has a market capitalization of $622.77 million. The company earns $-95,820,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.
How many employees does Century Therapeutics have?: The company employs 170 workers across the globe.
How can I contact Century Therapeutics?: The official website for the company is www.centurytx.com. The company can be reached via phone at 267-817-5790 or via email at investor.relations@centurytx.com.

This page (NASDAQ:IPSC) was last updated on 12/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial